A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
Key facts
- Where
- Nara, JapanSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Where in Japan
- Nara Medical UniversityNara, JapanTaking people
- Nara Prefecture Seiwa Medical CenterNara, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cedars-Sinai Medical Center
- Trial code
- NCT03193541
- Record updated
- 4 February 2026
- Original description
To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of patients with microscopic hematuria.Read full original descriptionShow less
To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of patients with microscopic hematuria.
Inclusion: Age 18 years or older; Have documented or reported microscopic hematuria within 3 month of study enrollment; Willing and able to give written informed consent.
Exclusion: Have recent genitourinary instrumentation (within 10 days prior to signing consent); Have history of BCa; History of previous cancer (excluding basal and squamous cell skin cancer); Have a known active urinary tract infection or urinary retention; Have active stone disease (renal or bladder) or renal insufficiency (creatinine >2.0 mg/dL); Have ureteral stents, nephrostomy tubes or bowel interposition; Be unable or unwilling to complete the hematuria evaluation (i.e., cystoscopy and upper tract imaging).